Literature DB >> 1659106

Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas.

D C Longee1, C J Wikstrand, J E Månsson, X He, G N Fuller, S H Bigner, P Fredman, L Svennerholm, D D Bigner.   

Abstract

Monoclonal antibodies (mAbs) recognizing the disialoganglioside II3(NeuAc)2GgOse3Cer (GD2) were produced by immunizing mice with the GD2-expressing neuroblastoma cell line LAN-1 and a prefusion boost with purified GD2 coupled to Salmonella minnesota. Two IgM mAbs were isolated which demonstrated high levels of reactivity (binding ratios in excess of 100) with GD2 by solid-phase radioimmunoassay and positivity in high-performance thin-layer chromatography (HPTLC) immunostain; only one (DMAb-20) was subsequently shown by analysis with a panel of defined ganglioside species to be specific for the minimum epitope of GD2 GalNAc beta 1-4(NeuAc alpha 2-8-NeuAc alpha 2-3)Gal-, DMAb-20 was used to evaluate the expression of GD2 by malignant glioma and medulloblastoma cell lines using cell surface radioimmunoassay. indirect membrane immunofluorescence. HPTLC immunostain, and densitometric analysis of extracted gangliosides from selected cell lines. Sixteen of 20 (80%) malignant glioma and 5 of 5 medulloblastoma cell lines reacted with DMAb-20; in agreement with previous studies, 5 of 5 neuroblastoma and 2 of 3 melanoma cell lines also reacted with DMAb-20, GD2 was proportionally increased in the glioma and medulloblastoma cell lines relative to levels in normal brain, as determined by densitometric analysis. In a phenotypic survey of malignant glioma biopsies, tumor cells in 24 of 30 (80%) cases stained positively with DMAb-20. Reactive astrocytes, both within the adjacent to tumors, were frequently intensely stained. Among the morphological variants of glioblastoma examined, the most intense staining with DMAb-20 was observed in neoplastic gemistocytes, with the weakest or absent staining in small cell glioblastomas. As GD2 is a commonly expressed surface antigen of gliomas and medulloblastomas, expression of which is retained in tissue culture. DMAb-20 will be useful in determining the functional role of GD2 in cell-cell interaction, adhesion, and invasion, and in defining altered growth control mechanisms of central nervous system neoplasms in in vitro models.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659106     DOI: 10.1007/bf00310922

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  40 in total

1.  Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method.

Authors:  L SVENNERHOLM
Journal:  Biochim Biophys Acta       Date:  1957-06

2.  Experimental studies on the pathogenesis of leucodystrophies. I. The effect of intracerebrally injected sphingolipids in the rat's brain.

Authors:  Y Olsson; P Sourander; L Svennerholm
Journal:  Acta Neuropathol       Date:  1966-03-04       Impact factor: 17.088

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies.

Authors:  C J Wikstrand; D D Bigner
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

5.  Lipid composition of human glial tumour and adjacent brain.

Authors:  D E Slagel; J C Dittmer; C B Wilson
Journal:  J Neurochem       Date:  1967-07       Impact factor: 5.372

6.  Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.

Authors:  F D Vrionis; C J Wikstrand; P Fredman; J E Månsson; L Svennerholm; D D Bigner
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

7.  Gangliosides in the human glioma cell line U-118 MG grown in culture or as xenografts in nude rats.

Authors:  P Fredman; J E Månsson; S H Bigner; C J Wikstrand; D D Bigner; L Svennerholm
Journal:  Biochim Biophys Acta       Date:  1990-08-06

8.  Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.

Authors:  N K Cheung; U M Saarinen; J E Neely; B Landmeier; D Donovan; P F Coccia
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

9.  Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med.

Authors:  H S Friedman; P C Burger; S H Bigner; J Q Trojanowski; C J Wikstrand; E C Halperin; D D Bigner
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

10.  Gangliosides of human cerebral astrocytomas.

Authors:  T D Traylor; E L Hogan
Journal:  J Neurochem       Date:  1980-01       Impact factor: 5.372

View more
  11 in total

1.  Integrins mediate adhesion of medulloblastoma cells to tenascin and activate pathways associated with survival and proliferation.

Authors:  Paul Fiorilli; Darren Partridge; Izabela Staniszewska; Jin Y Wang; Maja Grabacka; Kelvin So; Cezary Marcinkiewicz; Krzysztof Reiss; Kamel Khalili; Sidney E Croul
Journal:  Lab Invest       Date:  2008-09-15       Impact factor: 5.662

2.  In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line.

Authors:  P Fredman; C J Wikstrand; J E Månsson; G Reifenberger; S H Bigner; A Rasheed; L Svennerholm; D D Bigner
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

3.  Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.

Authors:  Maxim Yankelevich; Sri Vidya Kondadasula; Archana Thakur; Steven Buck; Nai-Kong V Cheung; Lawrence G Lum
Journal:  Pediatr Blood Cancer       Date:  2012-06-15       Impact factor: 3.167

4.  Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates.

Authors:  K Kramer; N K Cheung; J Humm; G DiResta; E Arbit; S Larson; R Finn; M Rosenblum; H Nguyen; G Gonzalez; C Liu; Y F Yang; M E Mendelsohn; A P Gillio
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

5.  Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells.

Authors:  Jiao Wang; Sandra Toregrosa-Allen; Bennett D Elzey; Sagar Utturkar; Nadia Atallah Lanman; Victor Bernal-Crespo; Matthew M Behymer; Gregory T Knipp; Yeonhee Yun; Michael C Veronesi; Anthony L Sinn; Karen E Pollok; Randy R Brutkiewicz; Kathryn S Nevel; Sandro Matosevic
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-09       Impact factor: 12.779

6.  Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors.

Authors:  E Arbit; N K Cheung; S D Yeh; F Daghighian; J J Zhang; C Cordon-Cardo; K Pentlow; A Canete; R Finn; S M Larson
Journal:  Eur J Nucl Med       Date:  1995-05

7.  Glycolipids of a human glioma cell line bearing receptors for platelet-derived growth factor (PDGF).

Authors:  A J Yates; J D Agudelo; C C Sung
Journal:  Lipids       Date:  1992-04       Impact factor: 1.880

8.  GD2 oligosaccharide: target for cytotoxic T lymphocytes.

Authors:  X J Zhao; N K Cheung
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

Review 9.  Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.

Authors:  Bassel Nazha; Cengiz Inal; Taofeek K Owonikoko
Journal:  Front Oncol       Date:  2020-07-07       Impact factor: 6.244

Review 10.  CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.

Authors:  Michael C Burger; Congcong Zhang; Patrick N Harter; Annette Romanski; Florian Strassheimer; Christian Senft; Torsten Tonn; Joachim P Steinbach; Winfried S Wels
Journal:  Front Immunol       Date:  2019-11-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.